Compare Regeneron Pharmaceuticals Inc (REGN) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.

The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.

TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $32.66, down 2.07% daily. Technical indicators are bearish overall, with moving averages signaling strong selling pressure, though oscillators are neutral and short-term RSI levels suggest potential oversold conditions. The fund provides 3x daily leveraged exposure to long-term U.S. Treasuries, making it highly sensitive to interest rate movements and unsuitable for long-term holding due to daily leverage reset mechanics.

The outlook for TMF hinges entirely on the direction of long-term bond yields, with potential for sharp gains if rates fall but severe losses if they rise. It represents a high-risk, tactical instrument for short-term traders speculating on Treasury price movements, not a fundamental equity investment. Key risks include volatility decay from daily resets and macroeconomic shifts in monetary policy.